comparemela.com

Latest Breaking News On - Basket study - Page 2 : comparemela.com

Genmab A/S (GMAB) Q4 2020 Earnings Call Transcript

Genmab A/S (GMAB) Q4 2020 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Genmab A/S (NASDAQ: GMAB) Q4 2020 Earnings Call [Operator Instructions] During this telephone conference you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. Genmab is not under an obligation to update statements regarding the future, nor to confirm such statements in relation to actual results unless this is required by law. Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy.

Tah ahmadiCarsten lonborg madsenPeter verdult citiMichael novod nordeaAnthony paganoJudith klimovskyAnthony manciniWimal kapadiaTrung huynhJanssen duobodyMatthew harrison morgan stanleyMichael schmidt guggenheimMichael novodPeter verdultMatthew harrisonJonathan chang

Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering

Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registration study in head and neck cancer in the United States in 2021 Following previously reported preliminary data regarding the ability of NBTXR3 to help transform anti-PD-1 non-responders into responders, the Company will provide the next update on its immuno-oncology phase I basket study evaluating NBTXR3 in combination with anti-PD-1 checkpoint inhibitors in the second quarter of 2021 The Company s expansive global development plan for NBTXR3, both as a single agent activated by radiotherapy and in combination with other anti-cancer therapies, will continue as planned

United statesUnited kingdomFrance generalRicky bhajunBrandon owensPorter novelliPierre louis germainNanobiotix immunoInternational organization for medical physicsNational cancer instituteCommunications departmentFrench financial markets authority autoritCompany nasdaqAmerican society of clinical oncology gastrointestinal symposiumExchange commission onInvestor relations department

vimarsana © 2020. All Rights Reserved.